famotidine has been researched along with Dementia Praecox in 15 studies
Famotidine: A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Olanzapine treatment is associated with substantial weight gain." | 9.11 | The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. ( Fuchs, C; Gil-Ad, I; Maayan, R; Poyurovsky, M; Tal, V; Weizman, A, 2004) |
| " We explored the use of SPEM as an outcome measure in an open-label clinical trial of famotidine, an H-2 antagonist, in patients with schizophrenia; famotidine has been proposed as an adjunctive medication, particularly for negative symptoms." | 9.08 | Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. ( Collins, JP; Deutsch, SI; Fay-McCarthy, M; Johri, SK; Kendrick, K; Rosenberg, PB; Rosse, RB; Tsui, LC; Wyatt, RJ, 1996) |
| "To evaluate the use and potential benefit of famotidine in the management of schizophrenia." | 8.80 | Famotidine in the management of schizophrenia. ( Martinez, MC, 1999) |
| "Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia." | 7.69 | Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. ( Collins, JP; Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Rosenberg, P; Rosse, RB; Tsui, LC; Wyatt, RJ, 1995) |
| "Famotidine (100 mg/day) was well tolerated by the study subjects." | 6.68 | An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. ( Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Prell, GD; Rosenberg, P; Rosse, RB; Tsui, LC; Wyatt, RJ, 1996) |
| "Histamine serves as a neurotransmitter and neuromodulator in the brain." | 5.30 | Oral famotidine: a potential treatment for children with autism. ( Linday, LA, 1997) |
| "Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier." | 5.29 | Famotidine as an adjunct treatment of resistant schizophrenia. ( Merskey, H; Oyewumi, LK; Plumb, C; Vollick, D, 1994) |
| "There is low-certainty evidence to suggest that metformin may be effective in preventing weight gain." | 5.22 | Pharmacological interventions for prevention of weight gain in people with schizophrenia. ( Agarwal, SM; Ahsan, ZA; Cohn, T; Duncan, MJ; Faulkner, GEJ; Hahn, M; Lockwood, JT; Remington, G; Stogios, N; Takeuchi, H; Taylor, VH, 2022) |
| "Olanzapine treatment is associated with substantial weight gain." | 5.11 | The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study. ( Fuchs, C; Gil-Ad, I; Maayan, R; Poyurovsky, M; Tal, V; Weizman, A, 2004) |
| " We explored the use of SPEM as an outcome measure in an open-label clinical trial of famotidine, an H-2 antagonist, in patients with schizophrenia; famotidine has been proposed as an adjunctive medication, particularly for negative symptoms." | 5.08 | Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report. ( Collins, JP; Deutsch, SI; Fay-McCarthy, M; Johri, SK; Kendrick, K; Rosenberg, PB; Rosse, RB; Tsui, LC; Wyatt, RJ, 1996) |
| "To evaluate the use and potential benefit of famotidine in the management of schizophrenia." | 4.80 | Famotidine in the management of schizophrenia. ( Martinez, MC, 1999) |
| "Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia." | 3.69 | Famotidine adjunctive pharmacotherapy of schizophrenia: a case report. ( Collins, JP; Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Rosenberg, P; Rosse, RB; Tsui, LC; Wyatt, RJ, 1995) |
| "Patients with schizophrenia have lower histamine H1 receptor levels." | 2.78 | A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia. ( Ekelund, H; Ekelund, J; Haukka, J; Laitinen, J; Meskanen, K; Neuvonen, PJ; Panula, P, 2013) |
| "Famotidine (100 mg/day) was well tolerated by the study subjects." | 2.68 | An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. ( Deutsch, SI; Fay-McCarthy, M; Kendrick, K; Prell, GD; Rosenberg, P; Rosse, RB; Tsui, LC; Wyatt, RJ, 1996) |
| "Histamine serves as a neurotransmitter and neuromodulator in the brain." | 1.30 | Oral famotidine: a potential treatment for children with autism. ( Linday, LA, 1997) |
| "Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier." | 1.29 | Famotidine as an adjunct treatment of resistant schizophrenia. ( Merskey, H; Oyewumi, LK; Plumb, C; Vollick, D, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (66.67) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 3 (20.00) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agarwal, SM | 1 |
| Stogios, N | 1 |
| Ahsan, ZA | 1 |
| Lockwood, JT | 1 |
| Duncan, MJ | 1 |
| Takeuchi, H | 1 |
| Cohn, T | 1 |
| Taylor, VH | 1 |
| Remington, G | 1 |
| Faulkner, GEJ | 1 |
| Hahn, M | 1 |
| Thiyagarajamoorthy, DK | 1 |
| Arulanandam, CD | 1 |
| Dahms, HU | 1 |
| Murugaiah, SG | 1 |
| Krishnan, M | 1 |
| Rathinam, AJ | 1 |
| Meskanen, K | 1 |
| Ekelund, H | 1 |
| Laitinen, J | 1 |
| Neuvonen, PJ | 1 |
| Haukka, J | 1 |
| Panula, P | 1 |
| Ekelund, J | 1 |
| Andrade, C | 1 |
| Poyurovsky, M | 1 |
| Tal, V | 1 |
| Maayan, R | 1 |
| Gil-Ad, I | 1 |
| Fuchs, C | 1 |
| Weizman, A | 1 |
| Whiteford, HA | 1 |
| Stedman, TJ | 1 |
| McGrath, JJ | 1 |
| Welham, J | 1 |
| Pond, S | 1 |
| Oyewumi, LK | 1 |
| Vollick, D | 1 |
| Merskey, H | 1 |
| Plumb, C | 1 |
| Prell, GD | 2 |
| Rosse, RB | 5 |
| Deutsch, SI | 5 |
| Kendrick, K | 3 |
| Tsui, LC | 3 |
| Fay-McCarthy, M | 4 |
| Collins, JP | 3 |
| Rosenberg, P | 2 |
| Wyatt, RJ | 4 |
| Rosenberg, PB | 1 |
| Johri, SK | 1 |
| Linday, LA | 1 |
| Kendrick, KA | 1 |
| Martinez, MC | 1 |
| Kaminsky, R | 1 |
| Moriarty, TM | 1 |
| Bodine, J | 1 |
| Wolf, DE | 1 |
| Davidson, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Comparison of Bupropion SR and Placebo for Smoking Cessation[NCT00176449] | Phase 4 | 52 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia[NCT01946295] | Phase 2/Phase 3 | 140 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Histamine H2 Antagonism as Adjuvant Therapy in Treatment Resistant Schizophrenia[NCT00565175] | Phase 4 | 30 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for famotidine and Dementia Praecox
| Article | Year |
|---|---|
Pharmacological interventions for prevention of weight gain in people with schizophrenia.
Topics: Antipsychotic Agents; Betahistine; Famotidine; Fluoxetine; Humans; Melatonin; Metformin; Nausea; Niz | 2022 |
Famotidine in the management of schizophrenia.
Topics: Clinical Trials as Topic; Famotidine; Histamine H2 Antagonists; Humans; Schizophrenia | 1999 |
5 trials available for famotidine and Dementia Praecox
| Article | Year |
|---|---|
A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Famoti | 2013 |
A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Famoti | 2013 |
A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Famoti | 2013 |
A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant schizophrenia.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Famoti | 2013 |
The effect of famotidine addition on olanzapine-induced weight gain in first-episode schizophrenia patients: a double-blind placebo-controlled pilot study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Interaction | 2004 |
Smooth pursuit eye movements in the evaluation of famotidine adjunctive therapy of schizophrenia: a preliminary report.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Famotidine; Histamine H2 Antagonists; Humans; Neuro | 1996 |
An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy.
Topics: Adult; Dose-Response Relationship, Drug; Famotidine; Female; Humans; Male; Middle Aged; Prognosis; P | 1996 |
Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data.
Topics: Adolescent; Adult; Antipsychotic Agents; Drug Therapy, Combination; Famotidine; Histamine H2 Antagon | 1993 |
8 other studies available for famotidine and Dementia Praecox
| Article | Year |
|---|---|
Marine Bacterial Compounds Evaluated by In Silico Studies as Antipsychotic Drugs Against Schizophrenia.
Topics: Antipsychotic Agents; Binding Sites; Computational Biology; Drug Interactions; Famotidine; Furans; H | 2018 |
Famotidine augmentation in schizophrenia: hope or hype?
Topics: Antipsychotic Agents; Chronic Disease; Drug Synergism; Evidence-Based Medicine; Famotidine; Histamin | 2013 |
An open-label study of famotidine as a treatment for schizophrenia.
Topics: Adult; Famotidine; Haloperidol; Humans; Middle Aged; Schizophrenia; Treatment Outcome | 1995 |
Famotidine as an adjunct treatment of resistant schizophrenia.
Topics: Adult; Brain; Famotidine; Female; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schiz | 1994 |
Apparent absence of famotidine-antipsychotic drug interactions in patients with chronic schizophrenia.
Topics: Antipsychotic Agents; Brain; Chronic Disease; Famotidine; Histamine H2 Antagonists; Humans; Schizoph | 1996 |
Famotidine adjunctive pharmacotherapy of schizophrenia: a case report.
Topics: Famotidine; Humans; Male; Middle Aged; Molindone; Schizophrenia | 1995 |
Oral famotidine: a potential treatment for children with autism.
Topics: Administration, Oral; Adult; Animals; Autistic Disorder; Child; Famotidine; Histamine; Histamine H2 | 1997 |
Effect of famotidine on deficit symptoms of schizophrenia.
Topics: Adult; Famotidine; Humans; Male; Peptic Ulcer; Receptors, Histamine; Schizophrenia | 1990 |